PCIB
vs
O
Oslo OBX
PCIB
Over the past 12 months, PCIB has underperformed Oslo OBX, delivering a return of -81% compared to the Oslo OBX's +20% growth.
Stocks Performance
PCIB vs Oslo OBX
Performance Gap
PCIB vs Oslo OBX
Performance By Year
PCIB vs Oslo OBX
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
PCI Biotech Holding ASA
Glance View
PCI Biotech Holding ASA engages in the research and development of biopharmaceutical products for cancer treatment. The company is headquartered in Oslo, Oslo. The company went IPO on 2008-06-18. Its activities are focused on the commercialization of a patented photochemical drug delivery technology for use in the localized cancer treatment. The Company’s products are based on the Photochemical Internalization (PCI) technology for light-directed drug delivery, used to enhance the effect of drugs by targeted illumination of the diseased areas of the body. The company focuses primarily on the drug candidate Amphinex, developed for treatment of head and neck cancer and bile duct cancer, as well as on the development of PCI for vaccination. As of December 31, 2011, it had a wholly owned subsidiary PCI Biotech AS and an affiliate PCIO Biotech Utibu, located in Iceland.